Overview

Long-Term Study of Gabapentin Enacarbil (GEn, XP13512) vs. Placebo in Patients With Restless Legs Syndrome.

Status:
Completed
Trial end date:
2007-11-01
Target enrollment:
Participant gender:
Summary
The primary objective of this trial is to assess the maintenance of efficacy of gabapentin enacarbil (GEn, XP13512) taken once daily in the long-term treatment of patients suffering from Restless Legs Syndrome (RLS).
Phase:
Phase 3
Details
Lead Sponsor:
XenoPort, Inc.
Treatments:
Gabapentin
gamma-Aminobutyric Acid